Grant: Operating Grant
Université du Québec à Trois-Rivières
$484,745.00
Inhibition of retroviral replication by the restriction factor TRIM5alpha, and its applications
EF 2009-10
Résumé
TRIM5alpha is a natural inhibitor of retroviruses, a family of viruses that includes HIV-1, the AIDS virus. Unfortunately, HIV-1
is not affected by the human version of TRIM5alpha, but it is efficiently inhibited by this protein in other primates. My laboratory is working at deciphering the mechanism of action of TRIM5alpha, in particular by identifying its cellular partners. We are also developing potential therapeutic gene transfer applications. This approach would involve modifying blood cells in AIDS patients so that they express a version of TRIM5alpha targeting HIV-1. Toward this end, we are using genetics to introduce mutations in human TRIM5alpha in order to boost its antiviral potential.
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
189010
Name
Berthoux Lionel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
Inhibition of retroviral replication by the restriction factor TRIM5alpha, and its applications
Programtype2
Operating Grants
Orgnameinp2
Université du Québec à Trois-Rivières
Cihramount2
$484,745
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Gene Therapy; Genetic Screens; Hiv-1; Innate Immunity; Molecular Virology; Retroviruses
Abstract
TRIM5alpha is a natural inhibitor of retroviruses, a family of viruses that includes HIV-1, the AIDS virus. Unfortunately, HIV-1
is not affected by the human version of TRIM5alpha, but it is efficiently inhibited by this protein in other primates. My laboratory is working at deciphering the mechanism of action of TRIM5alpha, in particular by identifying its cellular partners. We are also developing potential therapeutic gene transfer applications. This approach would involve modifying blood cells in AIDS patients so that they express a version of TRIM5alpha targeting HIV-1. Toward this end, we are using genetics to introduce mutations in human TRIM5alpha in order to boost its antiviral potential.
Competitiondate
200909
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Berthoux, Lionel
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $484,745~ $0~
